Ophthalmology

Second Sight Announces Expansion of Medicare Coverage for Argus II

SYLMAR, Calif.—Second Sight Medical Products (NASDAQ:EYES) recently announced that its Argus II Retinal Prosthesis System can now be covered by Medicare in seven of the 12 Medicare Administrative Contractor (“MAC”) jurisdictions nationwide, representing a total of 28 states, two territories, and the District of Columbia. By allowing Medicare coverage for Argus II, Novitas joins MACs CGS Administrators (jurisdiction J15), Palmetto GBA (jurisdiction JM), National Government Services (jurisdictions J6 and JK), and First Coast Service Options (jurisdiction JN). Second Sight said it continues to work with other MACs and payers to secure affirmative coverage policies for the Argus II and to…


Novaliq Names Gabriela Burian, MD, MPH as Chief Medical Officer

HEIDELBERG, Germany—Novaliq GmbH, a Heidelberg-based specialty pharmaceutical company focused on ophthalmology, has appointed Gabriela Burian, MD, MPH, as chief medical officer. She will report to the company’s managing director and CEO, Christian Roesky, PhD. Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading Novaliq’s global clinical development and regulatory efforts, as well as expanding the company’s proprietary ocular therapeutics pipeline. She has deep clinical knowledge and proven leadership in the areas of ophthalmic biomedical research and clinical translation, with specialized expertise in retina diseases. Previously, Dr. Burian held various leadership positions,…


Roger Valine Joins Grand Rapids Ophthalmology as Chairman

Robert J. Valine.​ GRAND RAPIDS, Mich.—Grand Rapids Ophthalmology (GRO) has appointed Roger J. Valine to its board of directors and he will serve as chairman. Valine is a former president and CEO of Vision Service Plan (VSP), now a part of VSP Global. Valine left the company in 2006. He began his 34-year career at VSP as a management trainee when the company had $10 million in annual revenue. During his tenure, the company grew to nearly $3 billion in revenue, provided vision care insurance to more than 55 million members, and was selected for eight consecutive years as one…


Avedro Appoints Thomas E. Griffin as Chief Financial Officer

Thomas E. Griffin.​ WALTHAM, Mass.—Avedro, a Waltham, Mass.-based ophthalmic pharmaceutical and medical device company specializing in corneal remodeling, has appointed Thomas E. Griffin as chief financial officer. Griffin has more than 25 years of executive management experience at emerging growth medical technology companies. He brings a track record of success, leading both early-stage and commercial companies throughout his career. A veteran finance executive, Griffin has spent his entire career in financial operations at medical technology and biotechnology companies. For 10 years and during the company’s initial public offering, he served as CFO of Entellus Medical, a medical technology company that…


Shire Names Snisarenko to Succeed Dempsey as Head of U.S. Ophthalmics Franchise

John Snisarenko.​ LEXINGTON, Mass.—Shire announced this week that John Snisarenko has been named group vice president and head of ophthalmics U.S. franchise. He succeeds Robert Dempsey, who has taken on a leadership role on Shire’s global business and has the new title of vice president and head of global ophthalmics. Snisarenko brings 30 years of experience in the pharmaceutical, biotech and medical device industries, many in ophthalmics leadership positions, to his new role at Shire. He has a proven track record in taking programs from development to successful commercialization, and helping businesses achieve high growth, according to Shire’s announcement. Most…